Bioequivalence study of Paroxetine immediate release (IR) tablets manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga sites in healthy Chinese subjects
Trial overview
Area under the concentration time curve (AUC) from time zero extrapolated to infinite time (AUC[0-inf]) of paroxetine A: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
AUC (0-inf) of paroxetine A: Fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
AUC (0-inf) of paroxetine B: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
AUC (0-inf) of paroxetine B: Fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
AUC from administration extrapolated to the last time of quantifiable concentration (AUC[0-t]) of paroxetine A: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
AUC(0-t) of paroxetine A: Fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
AUC (0-t) of paroxetine B: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
AUC (0-t) of paroxetine B: Fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
The observed maximum serum drug concentration (Cmax) of paroxetine A: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Cmax of paroxetine A: Fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Cmax of paroxetine B: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Cmax of paroxetine B: Fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Number of subjects with adverse events (AEs) and serious adverse events (SAEs)
Timeframe: Up to 30 days
Number of subjects with abnormal body temperature
Timeframe: Up to 30 days
Number of subjects with abnormal pulse rate
Timeframe: Up to 30 days
Number of subjects with abnormal respiratory rate
Timeframe: Up to 30 days
Number of subjects with abnormal blood pressure
Timeframe: Up to 30 days
Number of subjects with abnormal electrocardiogram (ECG) findings
Timeframe: Up to 30 days
Number of subjects with abnormal clinical chemistry parameters
Timeframe: Up to 30 days
Number of subjects with abnormal clinical hematology parameters
Timeframe: Up to 30 days
Number of subjects with abnormal urinalysis parameters
Timeframe: Up to 30 days
Time to reach Cmax (Tmax) of paroxetine A: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Tmax of paroxetine A: fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Tmax of paroxetine B: fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Tmax of paroxetine B: fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Terminal elimination rate constant (Lambda Z) of paroxetine A: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Lambda Z of paroxetine A: Fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Lambda Z of paroxetine B: fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Lambda Z of paroxetine B: fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Terminal elimination half-time (T1/2) of paroxetine A: Fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
T1/2 of paroxetine A: Fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
T1/2 of paroxetine B: fasting state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
T1/2 of paroxetine B: fed state
Timeframe: Pre-dose and 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose
Participation criteria
- Able to actively communicate with the investigator and to complete the study-related documents; able to understand the contents of the Informed consent form (ICF) and to sign a written ICF prior to any study-specific procedures.
- Males and females aged between 18 and 45 years inclusive, at the time of signing the informed consent.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Drug or alcohol abuse or dependency within one year prior to enrolment. History of regular alcohol consumption within one year of the study defined as: an average weekly intake of >14 drinks. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces [360 milliliter (mL)] of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- Able to actively communicate with the investigator and to complete the study-related documents; able to understand the contents of the Informed consent form (ICF) and to sign a written ICF prior to any study-specific procedures.
- Males and females aged between 18 and 45 years inclusive, at the time of signing the informed consent.
- Non-smoking healthy males and females as assessed by medical history and physical examination. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters which are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator (in consultation with the GSK Medical Monitor if necessary) agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Body weight>=50 kilograms (kg) (male) or 45kg(female) and Body mass index (BMI) 19.0 to 26.0 kg per meter square (kg/m^2) (inclusive).
- A female subject is eligible to participate if she is of: Child-bearing potential with negative pregnancy test as determined by serum or urine human chorionic gonadotropin (hCG) test at screening or prior to dosing and agrees to use the one of the defined contraception method during the study and until follow up contact.
- Male Subjects with female partners of child-bearing potential must agree to use one of the defined contraception methods during the study and until follow up contact.
- ALT, ALP and total bilirubin <=1.5x upper limit of normal (ULN) (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent).
- Based on single or averaged corrected QT interval (QTc) values of triplicate ECGs obtained over a brief recording period: QTc < 450 milliseconds (msec); or QTc < 480 msec in subjects with bundlebranch block.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Drug or alcohol abuse or dependency within one year prior to enrolment. History of regular alcohol consumption within one year of the study defined as: an average weekly intake of >14 drinks. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces [360 milliliter (mL)] of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- Unstable disease conditions; any laboratory measurements assessed by the investigator as clinically relevant (including ECG, hematology, biochemistry and urine analysis, etc.)；any disorder that might interfere with the absorption, distribution, metabolism or excretion of the study drug; or in the investigator’s opinion the disease may lead to safety concerns or interfere with the pharmacokinetics assessment.
- Subjects with concurrent or previous neuropsychological disorders, as assessed by Columbia Suicide Severity Rating Scale or by the investigator, have suicidal tendency, or have committed suicidal behavior/attempt.
- Known history of cerebral trauma, previous cerebral disorders, seizures or eating disorder, and other conditions that in the investigator’s opinion may increase the risk of seizures.
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- In subjects with concomitant use of monoamine oxidase inhibitors (MAOIs) (including linezolid, an antibiotic which is a reversible non-selective MAOIs and methylthioninium chloride (methylene blue)) or within two weeks of terminating treatment with MAOIs.
- In subjects with concomitant use of thioridazine or pimozide.
- The subject has participated in a clinical trial and has received an investigational product within 90 days prior to the first dosing day in the current study, or has participated in a clinical trial without receiving any investigational product within 30 days prior to the first dosing day in the current study.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months.
- Serum human immuno-deficiency virus (HIV) antibody or Syphilis antibody positive.
- A positive pre-study drug/alcohol screen.
- Known allergy to paroxetine IR Tablets or any of its components.
- Blood donation in excess of 400 mL in the 3 months prior to enrolment.
- Obvious evidence of active hematological diseases, or significant blood loss in the last 3 months. History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Lactating females or women of child bearing potential used oral or implanted contraceptives within the 30 days prior to enrolment, or received injections of chronically acting contraceptives in the 1 year prior to study initiation.
- Other conditions which, in the Investigator’s judgment, render subjects unsuitable for the clinical study.
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.